News about Global Pharma

AstraZeneca Completes USD 2B Equity Investment in Summit Therapeutics

AstraZeneca has completed its USD 2 billion equity investment in Summit Therapeutics to advance ivonescimab-based cancer treatment combinations.

Global Pharma | 06/10/2026 | By News Bureau

AstraZeneca and Daiichi Sankyo Partner with Summit on Datroway

AstraZeneca and Daiichi Sankyo enter clinical collaboration with Summit Therapeutics to evaluate Datroway in combination with ivonescimab across multiple tumor types.

Global Pharma | 05/10/2026 | By News Bureau

Bayer to Invest USD 2.2 Bilion in New US Manufacturing Site

Bayer will invest USD 2.2 billion in a new US manufacturing site in Ohio, creating around 600 jobs and expanding its US pharma operations.

Global Pharma | 05/10/2026 | By News Bureau

Sanofi, Regeneron Expand Alliance to Develop Four Long-Acting Antibodies

Sanofi and Regeneron expands their antibody collaboration to develop and commercialise four next-generation long-acting antibodies for immune-mediated diseases.

Global Pharma | 03/10/2026 | By News Bureau

HUTCHMED, AstraZeneca Submit US NDA for Orpathys-Tagrisso Combination

AstraZeneca submits a US FDA NDA for Orpathys plus Tagrisso in MET-driven NSCLC following EGFR-TKI progression, supported by positive Phase 3 SAFFRON PFS and OS results.

Global Pharma | 01/10/2026 | By News Bureau

US FDA Approves Teva's Denosumab Biosimilar DEGEVM

Teva’s DEGEVMA, a denosumab biosimilar to Xgeva, has gained US FDA approval for cancer-related bone complications and other indications.

Global Pharma | 30/09/2026 | By News Bureau |  294

US FDA Approves Olumiant for Pediatric Alopecia Areata

US FDA has approved Lilly’s Olumiant (baricitinib) for severe alopecia areata in patients aged 12 and older, based on the phase 3 BRAVE-AA-PEDS study.

Global Pharma | 28/09/2026 | By News Bureau

US FDA Approves Belzutifan-Lenvatinib for Advanced RCC

The US FDA has approved belzutifan in combination with lenvatinib for advanced renal cell carcinoma with a clear cell component.

Global Pharma | 28/09/2026 | By News Bureau

Merck's Remigromig Targets Wnt Pathway in Eye Disease

Merck’s remigromig meets the primary endpoint in the phase 2b/3 BRUNELLO study in adults with Diabetic Macular Edema (DME).

Global Pharma | 25/09/2026 | By News Bureau

Xenon Submits NDA for Azetukalner in Focal Seizures to US FDA

Xenon Pharmaceuticals has submitted an NDA to the US FDA for azetukalner in focal seizures, supported by data from the Phase 2b X-TOLE and Phase 3 X-TOLE2 trials.

Global Pharma | 21/09/2026 | By News Bureau |  101